You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cardiovascular conditions
  5. Lipid disorders

Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia

  • Technology appraisal guidance
  • Reference number: TA694
  • Published:  28 April 2021
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final draft guidance
  3. Draft guidance
  4. Invitation to participate

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 162 KB)

    Published:
    28 April 2021

Final draft guidance

  • Final draft guidance

  • Public committee slides (PDF 646 KB)

    Published:
    18 March 2021
  • Final appraisal document (PDF 294 KB)

    Published:
    18 March 2021
  • Committee papers (PDF 1.68 MB)

    Published:
    18 March 2021

Draft guidance

  • Draft guidance

  • Committee papers (PDF 8.81 MB)

    Published:
    11 December 2020
  • Public committee slides (PDF 1.14 MB)

    Published:
    11 December 2020
  • Public committee slides (PDF 891 KB)

    Published:
    11 December 2020
  • Appraisal consultation document (online commenting)

  • Appraisal consultation document (PDF version) (PDF 322 KB)

    Published:
    11 December 2020

Invitation to participate

  • Final scope (PDF 179 KB)

    Published:
    26 September 2019
  • Final stakeholder list (PDF 184 KB)

    Published:
    26 September 2019
  • Equality impact assessment (Scoping) (PDF 128 KB)

    Published:
    26 September 2019
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 251 KB)

    Published:
    26 September 2019
Back to top